On December 4, Gelonghui reported that hainan huluwa pharmaceutical group (605199.SH) announced that its stocks had hit the daily limit for seven consecutive trading days from November 26, 2024, to December 4, 2024, with a cumulative increase of 94.89%. The cumulative turnover ratio over the past seven trading days was 29.65%. The company's stock price increase is significantly higher than the average level of the sse composite index and the pharmaceutical manufacturing industry during the same period, which may indicate irrational speculation. The company particularly reminds investors that there has been no significant change in its fundamentals, and urges all investors to be aware of secondary market trading risks, make rational decisions, and invest prudently.
As of December 3, 2024, the company's static pe was 85.92, the rolling pe was 81.06, and the pb was 7.93. According to industry data released on the same day by the China Securities Index Co., Ltd. website, the industry average static pe of the pharmaceutical manufacturing industry is 28.10, the rolling pe is 27.92, and the pb is 2.74. The company's pe and pb are far above the industry average level.
